CSL Makes Landmark National-Level Pay-For-Performance Deal In Germany For Hemgenix

 
• By Francesca Bruce
  
CSL Behring's gene therapy Hemgenix is the subject of a first-of-a-kind pay for performance deal with Germany's national insurers. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Germany

More from Health Technology Assessment